Meeting Notes

Wednesday 23 September 2026

Attendees
Henrietta Hughes, Chair (Patient Safety Commissioner for England)
Tony Avery (NHS England / University of Nottingham)
Amit Aggarwal (ABPI)
Georgina Lawton (GS1 UK)
Richard Cattell (NHS England)
Thea Stein (Nuffield Trust)
Mike Durkin (Imperial College London)
Morag Punton (The Company Chemists’ Association)
Mercy Jeyasingham (MHRA)
Alan Clamp (Professional Standards Authority)
Habib Naqvi (NHS Race and Health Observatory)
Dafni Othonaiou (NHS England)
Nicola Byrne (National Data Guardian)
Reecha Sofat (University of Liverpool)
Meadhbha Monaghan (Patient and Client Council Northern Ireland)
Leanne Morgan (Department of Health (Northern Ireland))
Jeanette Dickson (Academy of Medical Royal Colleges)
Bola Owolabi (Care Quality Commission)
Rachel Power (Patients Association)
Peter Barry (NICE)
Kathie Cashell (General Pharmaceutical Council)
PSC staff also in attendance – Secretariat
Apologies
Peter Ellingworth (ABHI); Tony Dysart (PHSO); Sue Tranka (NHS Wales); Penny Pereira (The Q Community / NHS Alliance); Jacob Lant (National Voices); Alex Kafetz (CQC and HFEA); The Baroness Dame Clare Gerada; Karen Titchener (Patient Safety Commissioner for Scotland); Beth Fylan (NIHR). Peter Barry also passed on apologies from Adrian Hayter (NICE), and noted that he would like to be invited to future meetings.

MEETING NOTE

1.Welcome, apologies and Chair’s update
1.1The Chair, Henrietta Hughes, welcomed members to the second meeting of the Advisory Group for her second term.
1.2The Chair updated members on ongoing work, including the publication of the AI Commission recommendations, progress on electronic patient information, the national extension of Martha’s Rule to all accident and emergency departments, and publication of the new PSC strategy.
1.3The Chair noted ministerial and political changes, including the appointment of Yvette Cooper as Secretary of State for Health and Social Care, James Frith as Minister for Health Innovation, and Diana Johnson as Minister for Public Health and Patient Safety. She said her meeting with James Frith had covered medtech, innovation, the PSC’s strategic aims and AI readiness among providers.
1.4The Chair reported that the PSC continued to seek a substantive response to the Hughes Report and to understand barriers to action. She also updated members on the annual report, patient concerns relating to medicines and devices including diethylstilbestrol, Depo-Provera and propranolol, and work with DHSC on transparency of payments by device manufacturers.
2.Patient Safety Commissioner strategy
2.1The Chief of Staff for the Office of the Patient Safety Commissioner, Victoria Carbutt, thanked members for their contributions at the previous meeting and explained that feedback had been reflected in the revised second-term strategy. The strategy had also been tested with patient groups and healthcare partners.
2.2Victoria set out the three core themes of the strategy: safety and regulation; informed patient decisions; and equity, justice and patient safety leadership. She explained that future Advisory Group meetings would focus on selected deep dives rather than attempting detailed updates against every part of the strategy.
3.Cannabis-based medicinal products (CBMPs) prescribing
3.1Victoria introduced the PSC’s work on cannabis-based medicinal products (CBMPs). She explained that the work arose from concerns raised by system partners, members of the public and campaign groups, including Oliver’s Law, about whether current prescribing arrangements provide sufficient safeguards, visibility and oversight.
3.2Victoria emphasised that the project was not seeking to reopen debate on the legal status of medicinal cannabis or determine clinical use cases. The focus was on patient safety, excellence in prescribing and whether proportionate safeguards could be strengthened in a rapidly growing market involving Schedule 2 controlled medicines.
3.3Members discussed the rapid growth in prescribing and the importance of ensuring that prescribing arrangements for Schedule 2, unlicensed controlled medicines support appropriate assessment, informed consent and ongoing monitoring. The discussion explored access to clinical histories, continuity of care and professional oversight, particularly where care is provided remotely.
3.4Members noted challenges in data and patient safety intelligence, including the ability to link private prescribing information with wider health records and outcomes. The discussion also covered practical issues in processing Schedule 2 prescriptions and the need to understand cross-border prescribing arrangements.
3.5The group discussed the wider regulatory landscape, including the role of controlled drugs accountable officers, professional regulators, responsible officers and service regulation. Members highlighted the value of shared visibility, coordinated working and proportionate oversight of remote prescribing models.
3.6Members also reflected on the limits of the evidence base, the role of patient experience and anecdotal evidence, and the importance of clear information to support informed choices. The Chair said the PSC would return to the Advisory Group when more information was available and would align next steps with the ACMD review.
4.AI Commission
4.1The Chair updated members on the AI Commission report, which had been launched on 10 September following publication of research and engagement findings in June. She described the potential benefits of AI, including improved access, personalised prediction, faster diagnosis, screening, reduced administrative burden and better matching of capacity to demand.
4.2The Chair set out the Commission’s compass points: Safe, Fast and Trusted, putting people before technology. The Commission highlighted the need for human factors, ergonomics and usability, recognising that deployment of new technologies is sociotechnical and more often fails on the social aspect.
4.3The Chair summarised the Commission’s engagement. She said public support was conditional on confidence in governance, real-world monitoring, transparency, accountability and equity throughout the product lifecycle.
4.4Members welcomed the whole-system approach and discussed equity, regulation, workforce confidence, cybersecurity, misinformation, general-purpose AI tools, professional responsibility, incident reporting and mechanisms for capturing and sharing learning. The Chair noted that a government response was awaited and that discussions were continuing with NHS England, DHSC and MHRA on implementation and coordination.
5.GLP-1 project and digital prescribing
5.1Following a short break, the Chair introduced Sarnia Ward and Sammy Trup. Sarnia explained that she would be seconded part of the week from MHRA to the PSC to work on the GLP-1 project. Sammy, Policy and Operations Manager at the Office of the Patient Safety Commissioner, introduced the proposed project.
5.2Sammy explained that GLP-1 medicines were rapidly developing, with increasing use and changing routes of access. The project would not reassess clinical value or duplicate the work of regulators, professional bodies, policy teams or enforcement agencies. Its focus would be on patient safety across access, prescribing, supply, safeguards, regulation, enforcement, public information, adverse-event reporting, decision-making and consent.
5.3Through discussion, members highlighted risks associated with online pharmacies and digital prescribing, private prescribing, unregulated or counterfeit supply, advertising and misinformation, patient understanding, informed decision-making and gaps between organisational responsibilities.
5.4Members discussed the need to avoid duplication with existing work, including MHRA enforcement activity, GPhC work on online pharmacies and distance-selling standards, NHS weight-management programme work, drug utilisation dashboards, Yellow Card and LFPSE data, and wider work on fake pharmacies and social media sellers.
5.5The discussion explored where oversight and information-sharing arrangements may need to keep pace with changing routes of access. Members also raised patient preference, consumer demand, counterfeit supply, follow-up and monitoring, information sharing between private and NHS providers, eating-disorder expertise, patient voice, and the need to consider future products as well as GLP-1 medicines.
5.6The Chair summarised the discussion as exposing a gap between prescribing practice in remote environments compared with face-to-face settings. She said the aim was not to restrict appropriate prescribing but to ensure excellence in prescribing regardless of the clinical setting.
6.Forward look
6.1Ebba Råhnängen, Diary Manager for the Patient Safety Commission, outlined upcoming engagements, including the ISQua conference in Dublin, the HSJ Patient Safety Congress in Telford, the Milken Institute Asia Summit in Singapore, a PHIN and Royal College of Physicians quality forum on ‘Patient safety in an online world’, a meeting with Lord Kamall, planned ministerial meetings and a follow-up event on the women’s health gap.
7.Any other business: Single Patient Record survey
7.1Nicola Byrne asked members to complete and share a survey for health and care professionals on the Single Patient Record. She explained that the work sought to understand what patients and professionals would need in order to trust the record, and encouraged circulation to a wide range of frontline professional networks.
8.Close
8.1The Chair thanked members for their participation, insights and assistance, and thanked the presenters. Future meeting dates would be placed in diaries and the team would follow up on the GLP-1 project. Members were invited to email any further insights.

ACTIONS

#ActionWho
(i)Progress CBMP work with system partners, including alignment with the ACMD review, further patient-group engagement and consideration of data linkage, professional oversight and information-sharing standards.PSC
(ii)Consider regulatory follow-up on remote prescribing risks, including the national intelligence network and engagement with controlled drugs accountable officer functions.PSC
(iii)Share or connect relevant GLP-1 work and evidence to inform the project.All Members
(iv)PSC office to lead the GLP-1 project and contact members who expressed interest in contributing further.PSC
(v)Complete and circulate the Single Patient Record survey and provide sharing text where requested.All Members / NDG office
(vi)Arrange future Advisory Group dates and circulate follow-up from the meeting.Secretariat / PSC

Links for reference:

Advisory Group Terms of Reference

PSC Second Term Strategy

AI Commission Report

Wednesday 20 May 2026

Attendees (in person)
Dr Amit Aggarwal (ABPI)
Prof Beth Fylan (NIHR / PSRC)
George Lawton (GS1 UK)
Helen Davenport (NHS England)
Prof Henrietta Hughes, Chair (Patient Safety Commissioner for England)
Mercy Jeyasingham (MHRA)
Morag Punton (The Company Chemists’ Association)
Dr Nicola Byrne (National Data Guardian)
Peter Ellingworth (ABHI)
Rachel Power (Patients Association)
Prof Reecha Sofat (University of Liverpool)
Prof Tony Avery (NHS England / University of Nottingham)
Dr Tony Dysart (PHSO)
(PSC staff also in attendance – Secretariat)
Attendees (online)

Alex Kafetz (Non-executive director of CQC, Authority member of the HFEA)

The Baroness Dame Clare Gerada
Karen Titchener (Patient Safety Commissioner for Scotland)
Kathie Cashell (General Pharmaceutical Council)
Patrick Murphy (on behalf of PSA)
Dr Peter Barry (NICE)
Richard Cattell (NHS England)
Sue Tranka (NHS Wales)
Thea Stein (Nuffield Trust)
Apologies
Alan Clamp (PSA)
Prof Bola Owolabi (CQC)
Prof Habib Naqvi (NHS Race and Health Observatory)
Jacob Lant (National Voices)
Dr Jeanette Dickson (Academy of Medical Royal Colleges)
Dr Mike Durkin

MEETING NOTE

1.Welcome and round table introductions
1.1The Chair, Henrietta Hughes, warmly welcomed everyone to the first meeting of the refreshed Advisory Group for her second term, and thanked both continuing and new members for joining.  Apologies had been received from Alan Clamp (Patrick Murphy deputising), Bola Owolabi, Habib Naqi, Jacob Lant, Jeanette Dickson, Mike Durkin.
1.2Brief round table and online introductions were made.  The Chair reflected on the vast and varied collective expertise reflected in the membership.
2.Chair’s opening remarks and scene setting
2.1Henrietta described her vision for collaborative working in a spirit of learning and sharing within a safe and trusted space. A summary meeting note would be added to the PSC website.
2.2Henrietta briefly recapped the role of Patient Safety Commissioner, an independent role first established in 2022 to drive improvement in the safety of medicines and medical devices by ensuring that patient voices are at the heart of the design and delivery of healthcare in England.
2.3In September last year PSC published a paper setting out what had been achieved during the first term (PSC Impact), including recommendations and calls to action made and how these had been responded to. 
2.4Following the Dash Review, the Office of the Patient Safety Commissioner was now hosted by MHRA but continued to be sponsored by DHSC.  The Dash Review stated that the wider remit adopted by the PSC should be integrated into DHSC to support improvements to patient safety and patient experience, including managing and learning from complaints. There was a new National Director of Patient Experience being recruited and Henrietta said she would hand over any broader work her office had previously done in this area.
2.5Sue Tranka shared the position in Wales saying the centring of patient voice in Wales was critical.  (See – Wales Listening to Patients – New Listening to People statutory guidance to improve how NHS Wales responds to concerns – NHS Wales Performance and Improvement ).
2.6Henrietta described the current work being undertaken by the National Commission into the Regulation of AI in Healthcare. Henrietta is the Deputy Chair of the Commission and chairs the Commission’s Health Systems Working Group, which examines the integration, resilience, and performance of health and regulatory systems in relation to the Commission’s priorities.
2.7The National Commission was undertaking a substantial research and engagement exercise, including a call for evidence, focus groups, and most recently that morning an ‘Ask me anything’ webinar. Henrietta would keep the Advisory Group updated. There was some discussion on the impact of AI and the need for safe deployment of AI as a medical device, including the impact on general practice with differing views expressed.
2.8Sue Tranka referred to the AI commission in Wales and that safeguards and regulation were being looked at with a view that AI should complement the human in the system. Beth Fylan referred to work generating an evidence base around the impact of technology on driving inequality.
2.9There was a brief discussion on the hidden safety issues associated with the increasing numbers of routes emerging for the public to buy medicines in different, often unconventional and illicit ways that was cause for concern. Rachel Power reported that the Patients Association had done a piece of work around why/how patients are accessing medicines online  (See Understanding patient experiences of buying medicines online | The Patients Association plus Patient experience survey May 2026 )
3.Draft Terms of reference
3.1Henrietta introduced the draft Terms of reference (ToR). No immediate comments were raised. Post-meeting note: After the meeting all members were invited by email to provide comments and feedback on the draft ToR by 28 May.
4.PSC Strategy and priorities
4.1Victoria Carbutt (PSC’s Chief of Staff) summarised the previous strategy adopted by the PSC which had focused on three broad themes – alignment of healthcare culture, patients’ voices in their care, patient voice in the delivery of healthcare. Victoria referred to progress made against each work area sitting under those themes, recognising some areas had resulted in notable positive outputs and were complete (e.g. establishing Martha’s Rule policy) whilst work on others is still ongoing.
4.2Henrietta added that every element of the strategy had started with patients, and had elevated patient voice be it through the Hughes Report or the Safety Gap report.  Henrietta described the policy sprints and co-production process for Martha’s Rule and the international inspiration that helped inform the policy. 
4.3Nicola Byrne suggested ‘meaningful consent’ might be preferable terminology to ‘informed consent’, as being informed is by itself insufficient for patients to be able to exercise genuine choice e.g. a power dynamic may exist within a healthcare situation that may hinder a patient from withholding their consent to something proposed by a healthcare professional. It was noted that regulators use different language when discussing the topic of consent, and Henrietta referred to the ‘principles of consent’ that were being produced collaboratively by the professional regulators. Henrietta suggested ‘What matters to you’ was the grounding question.
4.4Henrietta confirmed that other organisations represented on the Advisory Group but unable to join today’s meeting included the Academy of Medical Royal Colleges, CQC, NHS Race and Health Observatory, National Voices and that representation from Northern Ireland was being sought.
4.5The Patient Safety Principles which were one of the key deliverables in the first term, were developed following a public consultation process and would continue to inform and guide work going forward. The principles provided a framework for decision making, planning and collaborative working with patients as partners in a just and learning culture and were for everyone working in the healthcare system (see the explanatory text that sits behind each principle and a toolkit on how to use the principles on the PSC website).
4.6The Patient Safety Principles formed the foundation of the new draft strategy for the second term with three pillars (medicines, medical devices and patient safety), below which were potential priority areas of focus (draft at this stage) – these were aimed at improving the safety management system around medicines to reduce preventable harm, learning from previous patient experiences to encourage the safe deployment of medical devices, promoting the patient voice and driving equity across the healthcare system.
4.7Members split into groups to discuss the draft strategy before briefly reporting back in plenary. Feedback from the short discussions would be reflected upon during the process of refining the draft second term strategy. Post-meeting note: After the meeting all members were invited by email to provide further comments and feedback by 28 May.
5. Forward look
5.1In the coming weeks the Patient Safety Commissioner annual report for 2025-2026 would be finalised and laid before Parliament before the summer recess.  Finalising the draft strategy and work plan for the second terms would also be a priority.
6.2026 meeting dates
6.1Two further dates for meetings in 2026 had been circulated and calendar invites would follow for Wednesday 2 September and Tuesday 8 December.
7.AOB
7.1Henrietta thanked members for their comments and feedback and for contributing to a very positive first meeting; and asked members to connect on LinkedIn.

ACTIONS

  Action  Who  
(i)Send any comments on the draft Terms of Reference to commissioner@patientsafetycommissioner.org.uk by 28 MayAll members
(ii)Send any comments on the draft strategy for the second term (slides 7 & 8) to commissioner@patientsafetycommissioner.org.uk by 28 MayAll members
(iii)If not already done so please send a short biography and photo to commissioner@patientsafetycommissioner.org.uk for adding to the PSC website.All members
(iv)Identify if any important gaps in membership and make suggestionsAll members
(v)Send calendar invites for Sept and Dec meetingsSecretariat